AC Immune (ACIU) Interest Expenses (2015 - 2026)
AC Immune (ACIU) posted quarterly Interest Expenses of -$83005.3 for Q1 2026, down 38.2% year-over-year from -$134313.8 in Q1 2025, and up 80.37% quarter-over-quarter from -$422895.4 in Q4 2025.
AC Immune (ACIU) Interest Expenses (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Interest Expenses for 12 consecutive years, with -$83005.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 38.2% year-over-year to -$83005.3; the TTM figure through Mar 2026 stood at -$623800.2 (down 536.03% YoY), while the FY2025 annual figure was -$230370.5, down 51.74% from the prior year.
- Interest Expenses rose to -$83005.3 in Q1 2026 per ACIU's latest filing, from -$422895.4 in the prior quarter.
- Across five years, Interest Expenses topped out at $367517.6 in Q4 2023 and bottomed at -$422895.4 in Q4 2025.
- Historically, Interest Expenses has averaged -$42733.3 across 5 years, with a median of -$41244.6 in 2024.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 35305.57% — and 2025, when it plunged 1222.63%.
- AC Immune's Interest Expenses stood at $1038.0 in 2022, then surged by 35305.57% to $367517.6 in 2023, then plunged by 89.75% to $37670.2 in 2024, then slumped by 1222.63% to -$422895.4 in 2025, then soared by 80.37% to -$83005.3 in 2026.
- Business Quant data shows ACIU's Interest Expenses at -$83005.3 in Q1 2026, -$422895.4 in Q4 2025, and -$57505.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83,005.30 |
| Mar 31, 2026 | -83,005.30 |
| Dec 31, 2025 | -422,895.39 |
| Dec 31, 2025 | -422,895.39 |
| Sep 30, 2025 | -57,505.04 |
| Sep 30, 2025 | -57,505.04 |
| Jun 30, 2025 | -60,394.51 |
| Jun 30, 2025 | -60,394.51 |
| Mar 31, 2025 | -60,061.53 |
| Mar 31, 2025 | -60,061.53 |
| Dec 31, 2024 | 37,670.22 |
| Dec 31, 2024 | 37,670.22 |
| Sep 30, 2024 | -38,088.84 |
| Sep 30, 2024 | -38,088.84 |
| Jun 30, 2024 | -37,596.98 |
| Jun 30, 2024 | -37,596.98 |
| Mar 31, 2024 | -41,244.56 |
| Mar 31, 2024 | -41,244.56 |
| Dec 31, 2023 | 367,517.56 |
| Dec 31, 2023 | 367,517.56 |